Protocol Ledger

NCT04987203 · Phase III · COMPLETED

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Interventional Phase III clinical trial protocol NCT04987203 sponsored by AVEO Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-09 Enrollment: 343 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04987203
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)343 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04987203
Protocol FieldVerified Registry Value
NCT IdentifierNCT04987203
Consolidated Lead SponsorAVEO Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment343 participants (ACTUAL)
Registered Start Date2021-09-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI